TAT-PiET-PROTAC is a TAT-PiET modified by a proteolysis targeting chimera (PROTAC). TAT-PiET is a cell-penetrating peptide that targets the extra-terminal (ET) domain of BRD4. TAT-PiET-PROTAC disrupts the interaction between BRD4 and the oncogene JMJD6 in breast cancer, effectively inhibiting the growth of these cancer cells. Additionally, it combats endocrine resistance in ERalpha-positive breast cancer cells, making it a promising breast cancer inhibitor. TAT-PiET-PROTAC is also utilized in the synthesis/research of radiolabeled conjugate drugs (RDC).
Formula:
C145H239N53O35S
Target:
Epigenetic Reader Domain
* VAT and and shipping costs not included. Errors and price changes excepted
